MSA
ANIK icon

Mason Street Advisors’s Anika Therapeutics ANIK Stock Holding History

Mason Street Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5,301
Closed -$240K – 86
2020
Q4 		$240K Sell
5,301
-29
-0.5% -$1.1K ﹤0.01% 1380
2020
Q3 		$189K Sell
5,330
-2
-0% -$72 ﹤0.01% 1359
2020
Q2 		$201K Buy
5,332
+362
+7% +$11.9K ﹤0.01% 1339
2020
Q1 		$144K Hold
4,970
– – ﹤0.01% 1347
2019
Q4 		$258K Buy
4,970
+290
+6% +$16.8K ﹤0.01% 1328
2019
Q3 		$257K Sell
4,680
-62
-1% -$3.18K 0.01% 1303
2019
Q2 		$193K Buy
4,742
+178
+4% +$6.49K ﹤0.01% 1369
2019
Q1 		$138K Buy
4,564
+151
+3% +$5.17K ﹤0.01% 1478
2018
Q4 		$148K Buy
4,413
+92
+2% +$3.32K ﹤0.01% 1395
2018
Q3 		$182K Buy
4,321
+63
+1% +$2.49K ﹤0.01% 1399
2018
Q2 		$136K Buy
4,258
+182
+4% +$7.5K ﹤0.01% 1450
2018
Q1 		$203K Buy
4,076
+263
+7% +$14.9K ﹤0.01% 1337
2017
Q4 		$206K Buy
3,813
+101
+3% +$5.59K ﹤0.01% 1328
2017
Q3 		$215K Buy
3,712
+98
+3% +$5.12K 0.01% 1300
2017
Q2 		$178K Buy
3,614
+191
+6% +$8.8K ﹤0.01% 1324
2017
Q1 		$149K Buy
3,423
+228
+7% +$10.9K ﹤0.01% 1351
2016
Q4 		$156K Buy
3,195
+153
+5% +$7.07K ﹤0.01% 1325
2016
Q3 		$146K Buy
3,042
+240
+9% +$11.9K ﹤0.01% 1302
2016
Q2 		$150K Buy
2,802
+255
+10% +$12K ﹤0.01% 1260
2016
Q1 		$114K Buy
2,547
+188
+8% +$7.63K ﹤0.01% 1300
2015
Q4 		$90K Buy
2,359
+203
+9% +$7.77K ﹤0.01% 1337
2015
Q3 		$69K Buy
2,156
+136
+7% +$4.74K ﹤0.01% 1371
2015
Q2 		$67K Buy
2,020
+48
+2% +$1.71K ﹤0.01% 1397
2015
Q1 		$81K Buy
1,972
+106
+6% +$4.29K ﹤0.01% 1351
2014
Q4 		$76K Buy
1,866
+58
+3% +$2.27K ﹤0.01% 1765
2014
Q3 		$66K Buy
1,808
+322
+22% +$13.9K ﹤0.01% 1772
2014
Q2 		$69K Buy
1,486
+108
+8% +$4.8K ﹤0.01% 1761
2014
Q1 		$57K Sell
1,378
-425
-24% -$15.8K ﹤0.01% 1774
2013
Q4 		$69K Buy
+1,803
New +$55.6K ﹤0.01% 1775

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

Mason Street Advisors's ANIK Position: Q1 2021 in Review

Mason Street Advisors sold out of Anika Therapeutics (ANIK) in Q1 2021, closing a stake of 5,301 shares — an estimated $240K sold.

Mason Street Advisors first reported a position in ANIK in Q4 2013 and held it in 29 quarters. The position peaked at $258K in Q4 2019. 145 funds tracked by Wall St. Rank hold ANIK as of Q1 2021.

  • Mason Street Advisors reported no remaining Anika Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 5,301 Anika Therapeutics shares in Q1 2021, an estimated $240K.
  • Mason Street Advisors first reported a position in Anika Therapeutics in Q4 2013 and held it in 29 quarters.
  • Mason Street Advisors's Anika Therapeutics position peaked at $258K in Q4 2019.
  • 145 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.